NCT06964568View on ClinicalTrials.gov

TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

PHASE3RecruitingINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2031

Conditions
Esophageal CarcinomaRadiotherapyImmunotherapy
Interventions
DRUG

PD-1 inhibitor

PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.

RADIATION

TDLN-sparing radiotherapy

Tumor draining lymph nodes-sparing radiotherapy 50.4Gy/28Fx

RADIATION

Unlimited radiotherapy

Unlimited radiotherapy 50.4Gy/28Fx

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER